Jeffrey Jerome Ludwig net worth and biography

Jeffrey Ludwig Biography and Net Worth

Insider of Puma Biotechnology

Mr. Ludwig joined Puma Biotechnology as Chief Commercial Officer in March 2020. Mr. Ludwig was Vice President Oncology Sales for Astellas Pharma Inc., a multinational pharmaceutical company based in Japan, from 2019 until 2020, where he led multiple sales teams across several oncology therapeutic products, a significant label expansion in prostate cancer and a new launch in bladder cancer. Prior to joining Astellas, Mr. Ludwig worked at Amgen Inc., a multinational biopharmaceutical company based in California, from 2001 until 2019, where he most recently held the position of Vice President Oncology Sales from 2014 to 2019. During his tenure as Vice President of Oncology Sales, he led the sales organization through numerous successful launches and contributed to a multi-billion dollar portfolio of therapeutic and supportive care products. Before assuming the Vice President of Oncology Sales role, he successfully held various other leadership positions in both oncology sales and marketing. Prior to joining Amgen, Mr. Ludwig worked in various sales and marketing roles at Eli Lilly and Company from 1988 until 2001.

Mr. Ludwig holds a B.S. in business from Arizona State University, where he graduated with honors.

What is Jeffrey Jerome Ludwig's net worth?: The estimated net worth of Jeffrey Jerome Ludwig is at least $821.49 thousand as of January 2nd, 2025. Ludwig owns 108,951 shares of Puma Biotechnology stock worth more than $821,491 as of April 28th. This net worth evaluation does not reflect any other investments that Ludwig may own. Learn More about Jeffrey Jerome Ludwig's net worth.
How do I contact Jeffrey Jerome Ludwig?: The corporate mailing address for Ludwig and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Jeffrey Jerome Ludwig's contact information.
Has Jeffrey Jerome Ludwig been buying or selling shares of Puma Biotechnology?: Jeffrey Jerome Ludwig has not been actively trading shares of Puma Biotechnology over the course of the past ninety days. Most recently, Jeffrey Jerome Ludwig sold 9,437 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a transaction totalling $29,726.55. Following the completion of the sale, the insider now directly owns 108,951 shares of the company's stock, valued at $343,195.65. Learn More on Jeffrey Jerome Ludwig's trading history.
Who are Puma Biotechnology's active insiders?: Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?: During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company. Learn More about insider trades at Puma Biotechnology.
Information on this page was last updated on 1/7/2026.

Jeffrey Jerome Ludwig Insider Trading History at Puma Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/2/2025	Sell	9,437	$3.15	$29,726.55	108,951
7/17/2024	Sell	2,598	$3.70	$9,612.60	118,388
7/2/2024	Sell	6,051	$3.27	$19,786.77	120,986

Jeffrey Jerome Ludwig Buying and Selling Activity at Puma Biotechnology

Puma Biotechnology Company Overview

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Today's Range

Now: $7.54

$7.50

$7.73

50 Day Range

MA: $6.75

$5.70

$7.80

2 Week Range

Now: $7.54

$2.85

$7.90

Volume

227,778 shs

Average Volume

379,593 shs

Market Capitalization

$383.71 million

P/E Ratio

12.36

Dividend Yield

N/A

Beta

1.19